Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic disea ...

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

G/O Media is once again attempting to use AI to churn out content — while simultaneously warning that anything the AI ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with ... and death among patients with end-stage kidney disease is "very high," particularly from cardiovascular ...

Novo Nordisk and Eli Lilly have filed a motion to dismiss in the MDL over Ozempic and similar drugs. The defendants are asking the court to throw out 12 of the plaintiffs' 17 claims. The ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk ... high prices for the diabetes drug. It requires Novo Nordisk to cap out-of-pocket ...

BofA Securities believes that high-dose Rybelsus has comparable efficacy to Wegovy, and Novo Nordisk may still consider filing for it despite the competition. In conclusion, BofA Securities ...